Fidson Healthcare Plc, considered one of Nigeria’s main pharmaceutical firms, has set an bold purpose to attain World Well being Group (WHO) prequalification by 2025.
That is even because it has introduced its partnership with Liddie BE Ltd, a famend scientific analysis organisation, to conduct a Bioequivalence (BE) research on its chewable formulation of Albendazole tablets.
Albendazole is an FDA authorised medicine for the remedy of quite a lot of parasitic worm infections prevalent in Nigeria and lots of elements of the world. The BE research will probably be carried out underneath stringent regulatory tips that meet worldwide requirements and can examine the pharmacokinetics of the novel Albendazole formulation with the usual reference.
The CEO of Fidson, Dr. Fidelis Ayebae, on the joint press convention to announce this collaboration on Tuesday in Lagos, acknowledged that the partnership was a groundbreaking within the development of scientific analysis, being the primary Bioequivalence research to be carried out in Nigeria.
“We’re excited once more to be on the forefront of innovation and management within the healthcare business in Nigeria with this landmark effort. This research is a important step in direction of the WHO Prequalification of our model of chewable Albendazole tablets. This collaboration being the primary BE research in Nigeria and one of many first in Africa is a testomony to the success of indigenous efforts and imaginative and prescient which we’re very proud to guide,” he acknowledged.
The managing director of Liddie BE Ltd, Prof. Lara Orafidiya, added, “We’re completely happy to associate with Fidson on this important research. Our experience in scientific analysis will make sure that this product meets the required worldwide requirements for security and efficacy. We’re dedicated to contributing to the healthcare panorama in Nigeria by way of world-class scientific trials and analysis.”
The research outcomes are anticipated to supply key information to assist the WHO-PQ programme of the product. This initiative attests to each firms’ dedication to advancing healthcare entry and enhancing scientific outcomes in Nigeria and throughout the continent.
